This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Filomenko, R. Articles by Bettaieb, A. Search for Related Content PubMed PubMed Citation Articles by Filomenko, R. Articles by Bettaieb, A.

Atypical Protein Kinase C as a Target for Chemosensitization of Tumor Cells¹

INSERM U517, EPHE, Ecole Pratique des Hautes Etudes, IFR, Institut Féderatif de Recherche 100, Faculties of Medicine & Pharmacy, 21000 Dijon, France

Exposure of tumor cells to cytotoxic agents simultaneously activates a variety of intracellular signaling pathways. Some of these pathways involve enzymes from the protein kinase C (PKC) family of serine/threonine kinases. This family includes isoenzymes that negatively influence cell death, whereas other demonstrate an opposite effect. The present study analyzes the role of the atypical PKC isoform in tumor cell response to cytotoxic agents. Using a histone H1 phosphorylation assay, we showed that both tumor necrosis factor and etoposide activate PKC in U937 human leukemic cells. Stable transfection of a kinase-dead, dominant-negative PKC mutant in U937 cells decreases Bcl-2 expression while increasing the expression of Bax and several procaspases. This transfection also prevents etoposide-induced nuclear factor-B nuclear translocation and accumulation of X-linked inhibitor of apoptosis protein. PKC inhibition accelerates the occurrence of apoptosis in leukemic cells exposed to etoposide and tumor necrosis factor . This sensitization was confirmed in vitro by use of a clonogenic assay. In addition, PKC inhibition sensitized tumor cells grown in nude mice to etoposide. These results indicate that PKC isoform is a protective signals that is activated in tumor cells exposed to a cytotoxic agent. This inducible resistance factor thus appears an attractive target for chemosensitization of tumor cells.

This article has been cited by other articles:

				N. Buron, L. Guery, C. Creuzot-Garcher, P.-O. Lafontaine, A. Bron, M.-C. Rio, and E. Solary Trefoil Factor TFF1-Induced Protection of Conjunctival Cells from Apoptosis at Premitochondrial and Postmitochondrial Levels Invest. Ophthalmol. Vis. Sci., September 1, 2008; 49(9): 3790 - 3798. [Abstract] [Full Text] [PDF]

				L. Leseux, G. Laurent, C. Laurent, M. Rigo, A. Blanc, D. Olive, and C. Bezombes PKC {zeta} mTOR pathway: a new target for rituximab therapy in follicular lymphoma Blood, January 1, 2008; 111(1): 285 - 291. [Abstract] [Full Text] [PDF]

				C. Reis, N. Giocanti, C. Hennequin, F. Megnin-Chanet, M. Fernet, R. Filomenko, A. Bettaieb, E. Solary, and V. Favaudon A role for PKC{zeta} in potentiation of the topoisomerase II activity and etoposide cytotoxicity by wortmannin Mol. Cancer Ther., October 1, 2005; 4(10): 1457 - 1464. [Abstract] [Full Text] [PDF]

				S. K. Green, G. Francia, C. Isidoro, and R. S. Kerbel Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro Mol. Cancer Ther., February 1, 2004; 3(2): 149 - 159. [Abstract] [Full Text] [PDF]

				V. M.-D. Mas, H. Hernandez, I. Plo, C. Bezombes, N. Maestre, A. Quillet-Mary, R. Filomenko, C. Demur, J.-P. Jaffrezou, and G. Laurent Protein kinase Czeta mediated Raf-1/extracellular-regulated kinase activation by daunorubicin Blood, February 15, 2003; 101(4): 1543 - 1550. [Abstract] [Full Text] [PDF]

				C. L. Crowley-Weber, C. M. Payne, M. Gleason-Guzman, G. S. Watts, B. Futscher, C. N. Waltmire, C. Crowley, K. Dvorakova, C. Bernstein, M. Craven, et al. Development and molecular characterization of HCT-116 cell lines resistant to the tumor promoter and multiple stress-inducer, deoxycholate Carcinogenesis, December 1, 2002; 23(12): 2063 - 2080. [Abstract] [Full Text] [PDF]